Zealand Pharma advances obesity drugs with Phase 3 trials and launches $200M share buy-back program

Zealand Pharma reported strong Q1 2026 results, advancing its obesity treatments petrelintide and survodutide into Phase 3 trials after positive Phase 2 and 3 data showed significant weight loss and good tolerability. The company also established a new AI-driven research hub in Cambridge and secured access to a top AI supercomputer to accelerate drug discovery. Reflecting confidence in its pipeline and financial outlook, Zealand Pharma initiated a $200 million share buy-back program. Upcoming milestones include further clinical data presentations and regulatory submissions through 2026.